Evidence map›Paper›PMID 33344300›Full record

ArticleAutopsy & case reports2020

Full recovery of a stage IV cancer patient facing COVID-19 pandemic.

Anuraj Parmanande, Diana Simão, Mariana Sardinha, Ana Filipa Palma Dos Reis, Ana Sofia Spencer, João Vasco Barreira, Ricardo da Luz

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Autopsy & case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Anuraj ParmanandeCentro Hospitalar Universitário Lisboa Central, Medical Oncology Department. Lisboa, Portugal.ORCID 0000-0002-1549-5478
Diana SimãoCentro Hospitalar Universitário Lisboa Central, Medical Oncology Department. Lisboa, Portugal.ORCID 0000-0001-7638-9129
Mariana SardinhaCentro Hospitalar Universitário Lisboa Central, Medical Oncology Department. Lisboa, Portugal.ORCID 0000-0002-0220-538X
Ana Filipa Palma Dos ReisCentro Hospitalar Universitário Lisboa Central, Medical Oncology Department. Lisboa, Portugal.ORCID 0000-0002-9696-1759
Ana Sofia SpencerCentro Hospitalar Universitário Lisboa Central, Medical Oncology Department. Lisboa, Portugal.ORCID 0000-0002-1413-702X
João Vasco BarreiraCentro Hospitalar Universitário Lisboa Central, Medical Oncology Department. Lisboa, Portugal.ORCID 0000-0002-4527-5660
Ricardo da LuzCentro Hospitalar Universitário Lisboa Central, Medical Oncology Department. Lisboa, Portugal.ORCID 0000-0001-9700-3870
Centro Hospitalar de Lisboa Central · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19), first recognized in Wuhan, China, was recently declared a global pandemic by the World Health Organization (WHO). Advanced age and comorbid disease, well-known characteristics in the solid tumor population, have been reported as risk factors for severe disease and death. Cancer-related immunosuppression and its treatments also seem to play an active role in the prognosis, response, and clinical outcomes of these patients. The most effective combination therapy for COVID-19 is still under investigation, and the use of corticosteroids is controversial. Although, as a group, metastatic cancer patients are often considered not to be good candidates for ICU treatment, the individual prognosis should always come into consideration, even in a context of high pressure on medical facilities. We report the case of a stage IV prostate cancer patient infected with SARS-CoV-2 who required ICU admission and recovered from COVID-19 infection. Further studies are needed in order to identify accurate clinical prognostic criteria and provide the best treatment for these challenging patients.

Indexed as

CancerCOVID-19Critical careSARS-CoV-2Treatment Outcome

Identifiers

PMID33344300
PMCPMC7703164
OpenAlexW3033855333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.